Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 32 citing articles:

Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Sreenithya Ravindran, Shankar Munusamy
Journal of Cellular Physiology (2021) Vol. 237, Iss. 2, pp. 1182-1205
Closed Access | Times Cited: 61
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 71
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Shih‐Chieh Shao, Kai-Cheng Chang, Ming‐Jui Hung, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 61
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism (2021) Vol. 120, pp. 154799-154799
Closed Access | Times Cited: 54
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 75-85
Open Access | Times Cited: 53
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
The role of GLP-1 receptor agonists in managing type 2 diabetes
Noura Nachawi, PRATIBHA RAO, Vinni Makin
Cleveland Clinic Journal of Medicine (2022) Vol. 89, Iss. 8, pp. 457-464
Open Access | Times Cited: 24
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
Darren K. McGuire, Nikolaus Marx, Odd Erik Johansen, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 5, pp. 1073-1078
Closed Access | Times Cited: 37
Comparative Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers in Hypertensive Patients With Chronic Kidney Disease: A Systematic Review
Mouzafar A Mhmndar, Taranpreet Singh, Iram Fatima, et al.
Cureus (2025)
Open Access
Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review
H. Khan, Zarbakhta Ashfaq, J. Hamza, et al.
Cureus (2025)
Open Access
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 603-622
Open Access | Times Cited: 29
A 24‐week, randomized, double‐blind, active‐controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults
Yuan‐Di C. Halvorsen, John Paul Lock, Wenjiong Zhou, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 10, pp. 2248-2256
Open Access | Times Cited: 28
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
Vikas S. Sridhar, Habib Rahman, David Z.I. Cherney
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 55-68
Open Access | Times Cited: 22
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis
Beichen Tian, Yuanjun Deng, Yang Cai, et al.
Nephrology Dialysis Transplantation (2021) Vol. 37, Iss. 4, pp. 720-729
Closed Access | Times Cited: 20
Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Barış Afşar, Mads Hornum, Rengin Elsürer Afşar, et al.
Mitochondrion (2021) Vol. 58, pp. 72-82
Closed Access | Times Cited: 19
VDAC2 as a novel target for heart failure: Ca2+ at the sarcomere, mitochondria and SR
Paul B. Rosenberg
Cell Calcium (2022) Vol. 104, pp. 102586-102586
Open Access | Times Cited: 13
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest Adeghate, Huba Kalász, Saeeda Al Jaberi, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 2, pp. 85-93
Open Access | Times Cited: 16
SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus
Carlos King Ho Wong, Eric Ho Man Tang, Kenneth K. C. Man, et al.
Diabetes & Metabolism (2020) Vol. 47, Iss. 4, pp. 101196-101196
Open Access | Times Cited: 12
Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan
Hsien‐Yen Chang, Ying-Yi Chou, Wenze Tang, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 10
Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
Vicente Martínez‐Vizcaíno, Ana Díez‐Fernández, Celia Álvarez‐Bueno, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 12, pp. 2713-2713
Open Access | Times Cited: 9
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials
Lindsay E. Clegg, Yankang Jing, Robert C. Penland, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1101-1110
Closed Access | Times Cited: 6
Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus
Tingyu Cai, Yang Gao, Li Zhang, et al.
Medicine (2020) Vol. 99, Iss. 29, pp. e20735-e20735
Open Access | Times Cited: 4
Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes
Go Yokouchi, Takeshi Horio, Naoki Matsumoto, et al.
IJC Heart & Vasculature (2022) Vol. 43, pp. 101152-101152
Open Access | Times Cited: 3
Impact Of Dapagliflozin To Prevent Contrast Induced Nephropathy After Heart Catheterization And Percutaneous Coronary Intervention
Ahmed Mohammed ElSlalhy, Kamal Ahmed Marghany, Attia Morsy Shokr
Al-Azhar International Medical Journal /Al-Azhar International Medical Journal (2023) Vol. 4, Iss. 11
Open Access | Times Cited: 1
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?
Shailaja Kale, Abd A. Tahrani
Metabolism Open (2021) Vol. 10, pp. 100082-100082
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top